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Abstract
One of the major challenges facing the long term survival of neurons is their requirement to maintain efficient 
axonal transport over long distances. In humans as large, long-lived vertebrates, the machinery maintaining neuronal 
transport must remain efficient despite the slow accumulation of cell damage during aging. Mutations in genes 
encoding proteins which function in the transport system feature prominently in neurologic disorders. Genes known 
to cause such disorders and showing traditional Mendelian inheritance have been more readily identified. It has 
been more difficult, however, to isolate factors underlying the complex genetics contributing to the more common 
idiopathic forms of neurodegenerative disease. At the heart of neuronal transport is the rail network or scaffolding 
provided by neuron specific Microtubules (MTs). The importance of MT dynamics and stability is underscored by 
the critical role tau protein plays in MT-associated stabilization versus the dysfunction seen in Alzheimer’s disease, 
frontotemporal dementia and other tauopathies. Another example of the requirement for tight regulation of MT 
dynamics is the need to maintain balanced levels of post-translational modification of key MT building-blocks such as 
α-tubulin. Tubulins require extensive polyglutamylation at their carboxyl-terminus as part of a novel post-translational 
modification mechanism to signal MT growth versus destabilization. Dramatically, knock-out of a gene encoding a 
deglutamylation family member causes an extremely rapid cell death of Purkinje cells in the ataxic mouse model, 
pcd. This review will examine a range of neurodegenerative conditions where current molecular understanding 
points to defects in the stability of MTs and axonal transport to emphasize the central role of MTs in neuron survival. 
Keywords: Deglutamylation; Purkinje; Tubulin; Microtubules; 
Axonal transport; Dynactin; Kinesin
Introduction
The focus of this review will be the role of Microtubule (MT) 
stabilization and axonal transport as they relate to human pathology 
by looking at a series of inherited and sporadic conditions defined 
by neurodegeneration. In general, MTs form part of the cytoskeletal 
framework of all eukaryotes, and are primarily composed of tubular 
polymers of tubulin proteins with an outer diameter of ~25 nm [1]. 
Microtubules are formed by hetero-dimerization of α- and β-tubulin, 
the binding of GTP and subsequent incorporation of dimers into 
growing MT polymers (Figure 1). The dynamic stability of the MT will 
be favored or not depending upon β-tubulin’s binding of either GTP 
or GDP, respectively. For many years the tubulin protein family was 
thought to be specific to eukaryotes, but more recently a prokaryotic 
cell division protein FtsZ was uncovered as a ‘tubulin related protein’ 
[1]. Nonetheless, we now recognize that distinct tubulin post-
translational modifications within the eukaryotic MT polymer, such 
as glutamylation, make it possible for the cell to differentiate axonal-
MTs from other arrangements within the cell-body. With what 
appears to be increased neuronal MT complexity, comes the need for 
adequate regulation. Disease states will be discussed that range from 
rare, private gene mutations such as seen in the pcd mouse, to some of 
the most common human neuropathies such as Alzheimer’s disease, 
frontotemporal dementia and the tauopathies. 
Neuronal α-Tubulin post-translational modification defects
While various types of protein post-translational modification are 
well known, tubulin does require several additional forms that may not 
be well appreciated. For example, tubulin undergoes ligase mediated 
addition of glutamate and glycine residues [2,3]. However in neuronal 
MTs, tubulin glycylation is distinctly absent and glutamylation is of a 
specific form defined by the addition of one to six glutamate residues 
[4]. For both human and mouse, glutamylation and glycylation is 
orchestrated by a family of functional enzymes known as the ‘Tubulin 
Tyrosine Ligase – Like’ (TTLL) proteins. These range from TTLL1 
through TTLL13 with varying specificities and expression profiles [5]. 
Similarly, cleavage of glutamate side-chains is regulated by a family of 
six ‘Cytosolic Carboxy-Peptidases’ (CCPs), CCP1 through CCP6 [6,7]. 
Also, for reasons not well understood, α-tubulin of neuronal MTs go 
through cleavage of the carboxyl-terminal tyrosine residue followed by 
cleavage of the second to last gene encoded residue, a glutamate [8]. The 
final product is referred to as delta 2-tubulin (α2-tubulin) and it is this 
form of the protein that accumulates in stable MT assemblies within 
neurons [9] (Figure 2). 
Proof of the need to maintain tight regulation of these neuronal 
MT modifications, are now emerging. TTLL knock-out mice lack the 
ability to correctly add glutamate residues and display respiratory 
problems due to abnormal cilia beating on airway epithelial [10]. Cilia 
are structurally related to MTs as the cilia core consists of a MT-based 
cytoskeleton called the axoneme with nine outer microtubule doublets 
[11]. Conversely, the pcd mouse results from functional loss of the Nna1 
gene which encodes the deglutamylation enzyme, CCP1 [12]. CCP1, as 
well as CCP4 and CCP6 cleave glutamate residues from tubulin side-
chains as well as gene-encoded C-terminal glutamate residues. CCP5 is 
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Figure 1: The microtubule is a dynamic structure essential to axonal transport and neuron survival.  The center panel depicts the basic neuron structure, highlighting 
the role of kinesin family proteins for anterograde transport from the cell body; and the dynein molecular motor, essential for retrograde transport back from the axon 
terminal.  The upper panel represents and expansion from one isolated microtubule showing α-tubulin and β-tubulin as dynamic building blocks of the microtubule 
(side view and cross-section).  The lower panel is an expansion of the axon in cross-section, underscoring the role of tau protein in microtubule stabilization. 
Figure 2: The role of α-tubulin glutamate post-translational modification is depicted here, and can be appreciated by the rapid Purkinje Cell neurodegeneration which 
occurs in pcd mice via functional loss of the deglutamylation enzyme, CCP1.  At the top of the figure is the eleven carboxyl-terminal amino-acids of mouse α-tubulin. 
The terminal tyrosine reside, which is cleavable, is indicated in red.  (A), to the left, detyrosination and polyglutamylation generate an α-tubulin isoform that can be 
acted upon by cytosolic carboxy-Peptidases, CCP1, CCP4, and CCP6.  Each of these enzymes can cleave glutamate residues from the polyE side-chain down to the 
‘branch point’, and cleave the second last gene-encoded glutamate, creating the ∆2-Tub isomer.  The role of CCP5 alone is to specifically cleave the branch glutamate. 
(B), on the right side, addition of the branch point glutamate initiates this modification.  Thereafter, the situation where CCP1 or Nna1 is absent (pink shading), 
hyperglutamylation – neurodegeneration; is contrasted with the normal CCP1 present situation (no shading), defined by equilibrated polyglutamylation.  Redundant 
function of CCP4 and CCP6 does not compensate for CCP1 loss, as studies have shown CCP1 is the enzyme predominantly expressed in the neuron subset which 
undergoes degeneration in pcd mice.  This illustration was modified from figure 7 and supplemental material 1st reported by Rogowski et al., (2010).
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unique in its ability to remove the branch point glutamates (Figure 2). 
Pcd mice show overt ataxia beginning at 3 to 4 weeks of age, resulting 
from the rapid and dramatic degeneration of virtually all cerebellar 
Purkinje cells beginning at around P17 and is near complete by P45 
(Figure 3). Degeneration of cerebellar granule neurons (CGNs), follows 
thereafter, as well as the subsequent loss of other neuron populations 
[13]. While there is redundancy in CCP enzyme function, Nna1 shows 
the highest expression in cell populations most susceptible in pcd 
mice, and α-tubulin polyglutamylation levels were increased in these 
same regions [14]. Finally, partial rescue of the pcd phenotype was 
achieved by TTLL1 glutamylase knock-down, in an attempt to balance 
α-tubulin glutamylation, and as proof of principle. Motor coordination 
was improved by nearly 150% concomitant with the retention of a 
significant number Purkinje cells at day P40 [14].
 To date, mutations within the human CCP1-CCP6 protein 
orthologs have not been correlated with a specific ataxia syndrome 
reminiscent of the pcd mouse. Despite this, it is interesting to consider 
that hypomorphic mutations may underlie syndromes mapping 
to regions encompassing CCP deglutamylation gene loci. A non-
exhaustive list of potential candidates may include the following 
conditions listed in (Table 1).
While a human correlate to the pcd mouse has not been reported, 
a suggestive condition was recently discovered in sheep (Ovis aries). 
Missense mutation of the sheep CCP1 ortholog was linked with a 
phenotype similar to pcd mice. Affected sheep (n=19) were normal at 
birth, then progressive weakness and quadriplegia developed after the 
first week of life [15]. The authors define the condition as a lower motor 
neuron disease and noted that the R970P mutation locates within the 
catalytically active site, and showed complete segregation with the 
recessively inherited condition. 
Microtubule defects and motor dysfunction – Dynactin 
(retrograde)
Cytoplasmic dynein is a MT-based molecular motor protein 
that directly utilises the energy provided by ATP hydrolysis to allow 
retrograde transport of vesicles and organelles [16]. But it is the 
coordinated action of the dynactin macromolecular complex in 
combination with the dynein-motor that facilitates and orchestrates 
retrograde transport back to the cell body (Figure 1). And of the many 
proteins within the complex, dynactin 1 is the largest at ~150 kDa, 
directly binding to both MT and dynein [17]. 
Early studies with the dynactin 1 Drosophila ortholog, p150/
Glued, foreshadowed its critical role in neurons. Using a range of gene 
targeted and transgenic approaches, fly geneticists demonstrated that 
disruption of this protein results in a frequency increase of synaptic 
retraction events at the neuromuscular junction [18]. In 2003, Puls et al. 
were the first to link Dynactin-1 mutations with neural dysfunction. By 
studying a family showing dominant inheritance of a distal hereditary 
motor neuronopathy, (or lower motor neuron disease); they discovered 
that all nine affected family members harbored a Gly59Ser mutation. 
This substitution was predicted to “distort the folding of dynactin’s 
microtubule-binding domain” [19]. Taken together these findings 
demonstrate a link between dynactin-1 mutation and neuronopathy.
While the inherited neuronopathy described above is debilitating, 
it is not usually fatal when only lower motor neurons are involved. 
However, true motor neuron disease or Amyotrophic Lateral Sclerosis 
(ALS) is far more devastating and is not rare with an incidence of 
~1 in 40,000 [20]. Sporadic ALS (sALS) is a fatal, late-onset disorder 
Condition OMIM Band Interval Encoding gene
Spastic Paraplegia-19 607152 9q33-q34 CCP1, AGTPBP1
Spastic Paraplegia-41 613364 11p14.1-p11.2 CCP2, AGBL2
Spinocerebellar ataxia-32 613909 7q32-q33 CCP3, AGBL3
Primary ciliary dyskinesia-8 612274 15q24-q25 CCP4, AGBL1
Essential hereditary tremor-2 602134 2p25-p22 CCP5, AGBL5
Dystonia-9: episodic ataxia & 
spasticity 601042 1p33 CCP6, AGBL4
Table 1: Human conditions of unknown cause that map to defined genetic regions 
encompassing the six CCPs; CCP1 - CCP6.
Figure 3:  Purkinje cell degeneration in pcd5J homozygous mice. Here we see cerebellar sections for matched folia from P25 wild-type DBA/2J (WT) and P25 pcd5J 
homozygous mice (5J) immunostained with an anti-calbindin antibody and counterstained with DAPI. Although WT P25 cerebellum displays numerous Purkinje cell 
neurons with extensive dendritic arborization visible in the molecular layer (ML), the pcd5J P25 cerebellum reveals pronounced loss of Purkinje cells and dramatic 
degeneration of surviving Purkinje cells. The degree of Purkinje cell loss and degeneration observed in pcd5J homozygous mice is consistent with the disease’s natural 
history in pcd5J homozygous mice, suggesting that 5J is a severe allele. ML=molecular layer; PCL=Purkinje cell layer; GCL=granule cell layer.  Reproduced with 
permission from the corresponding author Albert R. La Spada (Chakrabarti et al., 2006). 
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characterized by rapid degeneration of upper and lower motor neurons 
(UMNs, LMNs), as well as bulbar neuron involvement [21]. And thus, 
in a study of 250 cases of sALS, three patients were found to have 
substitution mutations of the dynactin 1 protein. But in each of these 
individual cases the patients were distinguished from the Gly59Ser 
family by the addition of UMN signs and symptoms [22]. One of the 
three mutations described, Thr1249Ile, was subsequently identified 
in a range of control and neuropathy cohorts as follows: (i) 3 of 435 
controls; (ii) 1 of 374 Frontotemporal Dementia (FTD) patients; and 
(iii) 5 of 372 ALS patients [23]. As a consequence, it was concluded 
that the DCTN1 genetic loci likely represents a susceptibility gene 
to sALS as well as playing a direct role in rare, familial conditions. 
Partially overshadowing all of this may be the recent discovery that 
repeat expansions within the C9orf72 gene were found to be the most 
common cause of familial ALS (fALS), as well as a significant cause 
of sALS and FTD [OMIM: 614260], as discussed below. With C9orf72 
being added to the list of about a dozen genes known to directly cause 
fALS, only about 40% of fALS cases remain of unknown genetic cause 
[24]. What then may be the cause of the vast majority of all ALS cases 
where the cause(s) still remain undefined? ALS is a complex disease, 
where multiple genetic and environmental factors likely contribute 
to disease liability. Somatically acquired mutations within developing 
neurons, along with environmental insults and germ-line inheritance of 
hypomorphic mutations within a range of MT-based transport genes, 
are all likely to be involved and these may only be characterized with 
new, powerful, next-generation sequencing technologies.
Microtubule defects and motor dysfunction-Kinesin 
(anterograde)
 For axonal transport in the anterograde direction, the family of 
proteins known as the kinesins are indispensable (Figure 1). The 
kinesins are essentially the equivalent to the dynein-dynactin complex 
in that they are a family of molecular motor proteins that also use the 
hydrolysis of ATP to enable direct walking along MTs. But in this case 
specific cargos are moved in the anterograde direction. Kinesins do 
vary in shape but the prototype is a heterotetramer where two motor 
subunits form a protein dimer and then bind with two light chains. In 
most cases transported cargo is harnessed to the light chains [25].
Potentially the best example of an axonal neuropathy stemming 
from a kinesin gene defect was first reported in the journal Cell, in 2001. 
Charcot-Marie-Tooth disease (CMT), also known as Hereditary Motor 
Sensory Neuropathy (HMSN), is the most common inherited peripheral 
neuropathy in humans with a prevalence of 1 in 2500. CMT (or HMSN) 
is clinically characterized by weakness and atrophy of distal muscles, 
depressed or absent deep tendon reflexes, and mild sensory loss [26]. 
These disorders were traditionally classified into two forms differentiated 
only by electrophysiology testing. CMT type I, the demyelinating form 
showed reduced nerve conduction velocities (NCVs); and CMT type 
II, the axonal form showed normal NCVs, but reduced compound 
muscle action potentials. But in the current genomics era, more than 
40 genes are known to cause CMT and the phenotypic boundaries are 
becoming blurred (http://neuromuscular.wustl.edu/time/hmsn.html). 
Genes that cause demyelinating CMT (or type 1) tend to directly afflict 
Schwann cells, while those that cause the axonal forms tend to affect 
neurons more directly. The most common axonal form is CMT2A, 
and thus its initial mapping to chromosome 1p35-36 was an important 
landmark [27]. Then, as the kinesin encoding KIF1B gene was closely 
linked to the CMT2A genetic interval, it represented a strong candidate 
gene as it was known to transport mitochondria [28]. Dramatically, a 
Q98L mutation of the KIF1B β isoform was reported to segregate with 
disease in a Japanese CMT2A pedigree [29]. In this report, data in 
support of the kinesis hypothesis for CMT2A was strong: (i) Q98L was 
located to the ATP binding consensus; (ii) Q98L was shown to decrease 
ATPase activity; and (iii) Q98L blocked migration of KIF1B to the cell 
membrane. The authors were led to suggest KIF1Bβ haploinsufficiency 
was responsible for CMT2A neuropathy and explained the autosomal 
dominant inheritance. Finally, heterozygous kif1B+/− mice showed 
symptoms reminiscent of human CMT2A [29]. But enigmatically, no 
further links of KIF1Bβ mutation with CMT2A were reported. Several 
years later the true or common cause of CMT2A was described and 
the causal mutation of several previously reported CMT2A pedigrees 
were isolated within the mitofusin-2 gene, MFN2 [30]. Subsequent 
analysis has shown mitofusin-2 to be a mitochondrial membrane 
protein partially responsible for facilitating mitochondrial fusion and 
contributing to the maintenance and operation of the mitochondrial 
network [31]. And since the initial MFN2 mutation report, an array of 
gene mutations linked to CMT2A has been reported (OMIM: 609260).
The final point may be that mutation of another kinesin member, 
KIF5A (transporting a diverse range of cargos including mitochondria), 
causes autosomal dominant spastic paraplegia type 10 (SPG10) [32]. 
Since this discovery, a significant number of KIF5A point mutations, all 
located within the highly conserved motor domain have been reported 
in support of the kinesin haploinsufficiency hypothesis in SPG10, in 
which upper motor neurons are primarily affected (OMIM: 604187).
Axonal transport defects in motor neuron disease (MND, or 
ALS)
It is now accepted that just over a dozen genes are responsible for 
~60% of all fALS cases. But it is not known what may be common 
to each of the pathogenic pathways represented by these seemingly 
divergent genes. Given the unique sensitivity large motor neurons 
show to mutations in genes that are often ubiquitously expressed, 
it is reasonable to assume that there is a length dependent and 
energy requirement dependency to this sensitivity. Direct evidence 
also suggests axonal transport defects play an important role in 
neurodegeneration [33]. ALS1 results from mutations in the superoxide 
dismutase 1 gene (SOD1) and this form represents ~20% of fALS cases. 
But despite 2013 representing the 20 twenty year anniversary of the 
SOD1 discovery, the precise etiology of SOD1-mediated ALS still 
remains unclear [34]. As a potential point of mechanistic convergence, 
it is important to note that defects in anterograde axonal transport 
are one of the earliest pathologies observed in SOD1 mice [35]. Mice 
with dominant mutations of the dynein heavy chain gene (Dnchc1), 
Phe580Tyr, are known as legs at odd angles (Loa) mice. Loa mice show 
defects in retrograde axonal transport and loss of motor neurons [36]. 
Intriguingly, while the Loa mice show an age-related progressive loss 
of muscle tone and locomotor ability, no major reduction in life-span 
results. The experiment was undertaken then to cross SOD1G93A mice 
with Loa/+ mice to produce double-heterozygotes (Loa/SOD1G93A) and 
observe the resultant motor phenotype. In essence, could the defect in 
‘retrograde’ transport seen in Loa mice neutralize or partially neutralize 
the defect SOD1 mice harbor in ‘anterograde’ transport. SOD1G93A mice 
survive for an average of only 125 days, while Loa mice live a full life 
span. Thus, a conclusive result was found in that Loa/SOD1G93A mice 
survived for an average of 160 days, 28% greater than their SOD1G93A 
counterparts and disease onset was delayed [37]. In addition to the 
role of MTs, the related role of neurofilaments is clearly an overlapping 
aspect to the story. For example, an odd, over-accumulation of 
neurofilaments in parts of motor neurons is a hallmark of ALS, and 
Citation: Baird FJ, Bennett CL (2013) Microtubule Defects and Neurodegeneration. J Genet Syndr Gene Ther 4: 203. doi:10.4172/2157-7412.1000203
Page 5 of 7
Volume 4 • Issue 11 • 1000203
J Genet Syndr Gene Ther
ISSN: 2157-7412 JGSGT, an open access journal 
Neuro Genetics
mice with mutations in neurofilament genes have been found to have 
poorly functioning motor neurons [38]. But beyond this recognition, 
we will not focus on neurofilments in neurodegeneration, and consider 
it beyond the scope of this review.
Tau protein, Frontotemporal dementia and the Tauopathies
The microtubule-associated proteins (MAPs) bind directly to 
tubulin dimers via C-terminal domains normally leading to stabilization 
(Figure 1). The extent to which MAP proteins bind MTs is normally 
regulated via phosphorylation levels [39]. 
In 1989 it was established that six tau isoforms are produced by 
mRNA alternative splicing from the microtubule-associated protein 
tau gene, MAPT [40]. Critical to MT binding is a 31-amino acid repeat 
located in the carboxyl-terminus of tau that forms either three- or four-
repeat isoforms dependent on the exclusion or inclusion of exon 10. 
Normal cerebral cortex contains similar levels of 3-repeat and 4-repeat 
tau. The repeats and adjoining sequences constitute the MT-binding 
domain [40]. Significant interest is centred on MAPT mutations, or 
abnormal functioning and processing of the tau protein in association 
with a range of neurodegenerative conditions (OMIM: 157140). These 
include: Alzheimer’s disease (AD), Pick’s disease, FTD, cortico-basal 
degeneration and progressive supranuclear palsy.
The general tau hypothesis is that tau protein abnormalities initiate 
a pathologic cascade [41]. This is thought to begin when hyper-
phosphorylated tau pairs with other tau threads, and this catalyst 
expands to form neurofibrillary tangles within nerve cell bodies [42]. 
It is posited that the ensuing MT destruction fatally halts the essential 
transport system of neurons, ultimately leading to cell death [43].
Frontotemporal dementia is underscored as just one possible model 
for an inherited neurodegenerative condition resulting from MAPT 
mutations or tau dysfunction. FTD is characterized by progressive 
deterioration of the brain’s ‘frontal’ lobe, gradually expanding on 
occasion to include degeneration of the ‘temporal’ lobe. FTD is second 
only to AD in prevalence, accounting for ~20% of pre-senile dementia 
cases [44]. In FTD patients, symptoms normally begin between 45 to 65 
years of age, and commonly include behaviour changes and emotional 
dulling [44]. As with most of the better known neurodegenerative 
conditions, there is no cure, but new treatments for symptomatic relief 
are becoming available. 
The genetics of FTD is complex, but differs significantly from AD in 
that a far higher percentage of FTD cases directly result from inherited 
mutations at ~30-50%, whereas only 2-5% of AD is of the early-onset, 
inherited form. The three main genetic markers for FTD include the 
tau gene MAPT, as well as progranulin, PGRN, normally considered 
functioning as a cell growth regulator; and together MAPT and PGRN 
account for almost half of all familial-FTD [45]. More recently, the 
emergence of the C9orf72 gene (discussed above in reference to ALS), 
which is pathogenic by virtue of the presence of a hexanucleotide repeat 
expansion, was added to the list of important FTD genes. C9orf72, 
along with a range of other causal genes, account for the second half of 
all familial-FTD, which some subdivided as the FTLD-TDP43 forms [45].
FTDP-17 is an early-onset form of FTD caused by MAPT mutations 
and is characterized by the pathological aggregation of tau (OMIM: 
600274). These mutations play an important role in the study of tau 
aggregation which closely correlate with progression and severity of 
brain atrophy. Most FTDP-17 mutations localize in or near the MT 
binding repeat regions. And by generating expression vectors for 12 
different FTDP-17 mutants, it was demonstrated that many of these 
disease associated point mutations increased the propensity for in vitro 
aggregation and inhibited the MT stabilization ability of tau protein 
[46]. Studies directly looking at the effects on the frontotemporal lobe 
function specifically examined the FTDP-17 associated mutation, 
V337M. Transgenic mice (Tg-mice) over-expressing this human tau 
mutation from the brain specific Thy-1 promoter were compared with 
wild type (wt) Tg-mice. Comparing wt and TauV337M Tg-mice, a series 
of goal-directed, decision making tests indicated the tauV337M mutation 
selectively disrupts a subset of processes related to executive brain 
function [47].
The development of neurodegenerative treatments and the 
regulatory environment
Globally neurodegenerative diseases are already a large burden 
on healthcare systems. To care for its existing population of 
neurodegenerative patients affected by Alzheimer’s disease and other 
related disorders, the European Union (EU) spends approximately 
€130 billion per annum and this figure will only increase as 25% 
of the population will reach the age of 65 or older in 2030 [48]. The 
Alzheimer’s Association estimate that in 2013 the cost to the United 
States of America government will reach US$203 billion dollars per 
annum with the number expected to rise to $1.2 trillion by 2050 [49]. 
The spiralling cost of these diseases is one of the reasons behind 
the Food and Drug Administration Safety and Innovation Act of 
2012 (FDASIA), also known as the Prescription Drug User Fee Act V 
(PDUFA V) which has expanded two of the major bottle necks in the 
previous approval process. The Act intends to “facilitate and expedite 
development and review of new drugs to address unmet medical need 
in the treatment of a serious or life threatening condition” through the 
use of four programs: fast track designation, breakthrough therapy 
designation, accelerated approval and priority review designation 
[50]. These programs have resulted in the average review time being 
shortened to only 6 months, with some receiving approval even faster 
[51]. These changes should allow for more molecular therapies to 
become available for neurodegenerative diseases as they are intended 
to favour rare and/or life threatening conditions as well as those 
conditions affecting smaller numbers [52]. However, out of the thirteen 
FDA approved molecular therapeutic entities in the first half of 2013 
only one Tecfidera (dimethyl fumarate) by Biogen Idec was for a 
neurodegenerative disorder - multiple sclerosis [52]. 
Currently, there are over 897 open clinical trials for novel 
neurodegenerative disease treatments with 76 trials specific to MND/
ALS, 391 to Alzheimer’s disease and 28 to FTD [53]. Many of these trials 
will provide essential data towards demonstrating efficacy and safety 
within this new regulatory framework, especially as the use of meta-
analysis on existing trial data is now recommended; especially between 
EU and Asian regulatory bodies [53,54]. The new FDA regulations will 
also allow for more personalised gene therapies to be developed against 
unique biomarkers of orphan diseases [53]. This fast-track process 
is not without its risks as a single well designed trial with modified 
endpoints can be sufficient to gain approval; however that approval 
can be withdrawn if any product fails to meet ongoing approval criteria 
[54]. Within the next few years, we will see if any of those 897 trials 
yields an approved therapeutic under this new legislation.
Summary
In this review we have focused on the microtubule and some of 
its important component building blocks such as α-tubulin and the 
stabilizing role played by MAP proteins such as tau. Many aspects 
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of the review have been treated only briefly, examining the tip of 
the iceberg as it were; when in fact the pathogenic processes are 
extremely complex. For example, the dynamics of tau in its role of 
stabilizing MTs and the pathogenic onset of the tauopathies is very 
complex and its study could easily fill a successful career many times 
over. Our goal here was to draw together an overview of a range 
of primarily inherited disorders, where the mutations likely have a 
direct bearing on MT function within the neuron. We have looked 
at the role of glutamylation as one of the α-tubulin post-translation 
modifications used to maintain MT growth versus destruction. Yet 
few direct examples have been implicated in human disease showing 
Mendelian inheritance. Therefore, we highlighted the possibility that 
hypomorphic mutations of glutamylation or deglutamylation genes 
may be the cause of a range of human conditions where the genetic 
cause remains unknown. We have suggested hypomorphic mutations 
may be more likely as full knock-out of the human orthologs of these 
genes may cause embryonic lethality. Molecular motors responsible for 
either retrograde and anterograde were examined in light of a range 
of neurodegenerative conditions. These were found to result from 
mutation of important players in the dynein-dynactin complex as well 
as key kinesin family members. Throughout the review we have also 
tried to highlight the uniquely selective sensitivity neurons show in 
each condition, whether it is an ataxia, ALS, CMT, paraplegia or frontal 
lobe degenerative condition. And finally, we have included the latest 
changes to the regulatory environment which will facilitate the approval 
of next generation therapies for these often devastating conditions. 
This was looked at from the perspective of oversight bodies such as the 
FDA who now are actively working in concert with interested research 
bodies such as MDA and the ALS Association, as well as other global 
regulatory bodies such as the European Medicines Agency, in the hope 
that this group of patients may look forward to improved therapies in 
the near future.
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